OR6B2

Across TCGA pan-cancer cohorts, OR6B2 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated OR6B2 data layer compared with 9 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher OR6B2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated OR6B2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BLCA and UCEC are the cancer types where OR6B2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	All	0.139	0.626	.010	18	view →
UCEC	DFS	Median	II,III,IV	1.000	0.443	.035	4	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

OR6B2–BLCA (DFS)

Open the BLCA breakdown →